Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2017
Current Status of Hepatitis C Virus-Infected Maintenance Hemodialysis Patients in Japan.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Abe Takaya, Oomori Sou, Obara Wataru
Аннотация
Complete recovery using interferon therapy in Japanese hepatitis C virus (HCV)-infected dialysis patients is difficult to achieve because >70 % of the HCV genotypes observed in Japan are type 1. In 2016, new direct-acting antiviral drugs against HCV genotype 1 were reported to be effective and safe for HCV-infected hemodialysis patients. Although new direct antiviral therapy has become available, no large-scale studies evaluating the status of HCV infection in Japanese hemodialysis patients have been conducted since 2007. Therefore, we conducted a questionnaire survey to determine the current status of HCV infection in patients. Our results indicated that the HCV antibody prevalence was 5.02 %, and HCV RNA prevalence was 72.3 %. Genotype testing revealed that 62.1 % of patients had HCV genotype 1. New direct antiviral therapy may improve the survival of Japanese HCV-infected dialysis patients.